

## Institut Pasteur

[View the current Institut Pasteur Page on BioPortfolio.com](http://www.bioportfolio.com/biorporate/27906-Institut+Pasteur.html)

(<http://www.bioportfolio.com/biorporate/27906-Institut+Pasteur.html>)

### Contact Details:

25-28rue du Dr Roux

Paris

78015

France

Tel:

Fax:

Email: [rescom@pasteur.fr](mailto:rescom@pasteur.fr)

The Institut Pasteur is a non-profit foundation dedicated to the prevention and treatment of diseases through biological research, education and public health activities

### Recent Publications by Institut Pasteur:



- [Regulation of ploidy and senescence by the AMPK-related kinase NUA1.](#)  
*Senescence is an irreversible cell-cycle arrest that is elicited by a wide...* 21st November, 2009  
UMR8161, Institut de Biologie de Lille, CNRS/Universites de Lille 1 et- EMBO J. 2009 Nov 19. ([DOI Direct Link](#))
- [Purification, crystallization and preliminary X-ray diffraction experiments on the breakage-reunion domain of the DNA gyrase from Mycobacterium tuberculosis.](#)  
*Senescence is an irreversible cell-cycle arrest that is elicited by a wide...* 20th November, 2009  
Unite de Dynamique Structurale des Macromolecules, Departement de Biologie- Acta Crystallogr Sect F Struct Biol Cryst Commun. 2009 Nov 1;65(Pt ([DOI Direct Link](#)))
- [Integration of Distinct Intracellular Signaling Pathways at Distal Regulatory Elements Directs T-bet Expression in Human CD4+ T Cells.](#)  
*T-bet is a key regulator controlling Th1 cell development. This factor is...* 20th November, 2009  
Institut Pasteur, Immunoregulation Unit and Centre National de la- J Immunol. 2009 Nov 18. ([DOI Direct Link](#))
- [BioEssays 12/2009.](#)  
*T-bet is a key regulator controlling Th1 cell development. This factor is...* 19th November, 2009  
Institut Pasteur, 25-28 rue du Docteur Roux, 75015 Paris, France.- Bioessays. 2009 Nov 17;31(12). ([DOI Direct Link](#))
- [The complex eukaryotic transcriptome: unexpected pervasive transcription and novel small RNAs.](#)

- Over the past few years, techniques have been developed that have allowed...19th November, 2009  
 Unite de Genetique des Interactions Macromoleculaires, Institut Pasteur,- Nat Rev Genet. 2009  
 Dec;10(12):833-844. ([DOI Direct Link](#))
- [Toward a Unified Representation of Protein Structural Dynamics in Solution.](#)  
*An atomic resolution description of protein flexibility is essential for...*19th November, 2009  
 Protein Dynamics and Flexibility, Institute de Biologie Structurale- J Am Chem Soc. 2009 Nov  
 25;131(46):16968-16975. ([DOI Direct Link](#))
  - [Aspergillus fumigatus LaeA-mediated phagocytosis is associated with a decreased hydrophobin layer.](#)  
*Aspergillus fumigatus is the causal agent of the life threatening disease...*18th November, 2009  
 Department of Medical Microbiology and Immunology, University of- Infect Immun. 2009 Nov 16. ([DOI  
 Direct Link](#))
  - [Crystal Structure of the Extracellular Domain of a Bacterial Ligand-Gated Ion Channel.](#)  
*The crystal structure of the extracellular domain of the pentameric...*18th November, 2009  
 Institut Pasteur, Unite de Dynamique Structurale des Macromolecules, CNRS- J Mol Biol. 2009 Nov 13.  
 ([DOI Direct Link](#))
  - [Listeria rocourtiae sp. nov.](#)  
*A Listeria-like strain isolated in Austria from pre-cut lettuce fitted...*17th November, 2009  
 Institut Pasteur;- Int J Syst Evol Microbiol. 2009 Nov 13. ([DOI Direct Link](#))
  - [Control of flagellar gene regulation in Legionella pneumophila and its relation to growth phase.](#)  
*The bacterial pathogen Legionella pneumophila responds to environmental...*17th November, 2009  
 Institut Pasteur, Biologie des Bacteries Intracellulaires and CNRS URA- J Bacteriol. 2009 Nov 13. ([DOI  
 Direct Link](#))
  - [The relaxed requirements of the integron cleavage site allow predictable changes in integron target specificity.](#)  
*Integrans are able to incorporate exogenous genes embedded in mobile...*17th November, 2009  
 Institut Pasteur, Unite Plasticite du Genome Bacterien, CNRS URA 2171 and- Nucleic Acids Res. 2009  
 Nov 13. ([DOI Direct Link](#))
  - [Coactivation of Syk Kinase and MyD88 Adaptor Protein Pathways by Bacteria Promotes Regulatory Properties of Neutrophils.](#)  
*Neutrophils are one of the first lines of defense against microbial...*17th November, 2009  
 Institut Pasteur, Unite Regulation Immunitaire et Vaccinologie, 25 rue du- Immunity. 2009 Nov 11. ([DOI  
 Direct Link](#))
  - [Bone marrow-derived cells can acquire cardiac stem cells properties in damaged heart.](#)  
*ABSTRACT Experimental data suggest that cell-based therapies may be useful...*17th November, 2009  
 Institut Pasteur-Cenci Bolognetti Foundation, Department of Experimental- J Cell Mol Med. 2009 Nov  
 13. ([DOI Direct Link](#))
  - [Apolipoprotein A-V modulates insulin secretion in pancreatic beta-cells through its interaction with midkine.](#)  
*Apolipoprotein A-V is an important determinant of plasma triglyceride...*17th November, 2009  
 Universite Lille Nord de France, Inserm, UDSL and Institut Pasteur de- Cell Physiol Biochem.  
 2009;24(5-6):451-60. Epub 2009 Nov 4. ([DOI Direct Link](#))
  - [Human Apolipoprotein A-II Determines Plasma Triglycerides by Regulating Lipoprotein Lipase Activity and High-Density Lipoprotein Proteome.](#)  
*Introduction-Apolipoprotein (apo) A-II is the second most abundant...*17th November, 2009  
 Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau and Servei- Arterioscler Thromb Vasc  
 Biol. 2009 Nov 12. ([DOI Direct Link](#))

**Press Releases on Institut Pasteur:**

<a href="#">Reportlinker Adds Probiotics - A Global Update of Market Trends &amp; Opportunities</a>	25th November, 2009	Reportlinker	NEW YORK, Nov. 25 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Probiotics - A Global Update of Market Trends & Opportunities http://
<a href="#">Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent</a>	20th November, 2009	Boston Scientific Corporation	NATICK, Mass. and LONDON, Nov. 20 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration
<a href="#">Cequent Files its First IND with FDA: CEQ508, a tkRNAI Drug Candidate in Oncology</a>	12th November, 2009	Cequent Pharmaceuticals	CAMBRIDGE, Mass., Nov. 12 /PRNewswire/ -- Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, has announced
<a href="#">Video: Sanofi Pasteur Announces Final Results of U.S. Clinical Trials of Influenza A (H1N1) Vaccine in Adults and Children</a>	11th November, 2009	Sanofi Pasteur	SWIFTWATER, Pa., Nov. 11 /PRNewswire/ -- Sanofi Pasteur, the vaccines division of the sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), announced today the final analyses of data from clinical
<a href="#">MEDIA ALERT - Delivering On Our Public Health Commitment: An Update on A (H1N1) Vaccine Supply and Safety</a>	10th November, 2009	Sanofi Pasteur	WHAT Sanofi-aventis CEO Chris Viehbacher and Sanofi Pasteur President & CEO Wayne Pisano will discuss how the company is meeting the challenges of

## BioNews Results for Institut Pasteur



- [Big pharma offer H1N1 vaccines at US\\$6.5-10 a dose](#)  
People's Army Newspaper Online: Nov 22 2009 7:42AM Matching: institut pasteur
- [Pfizer inks pact with DNDi to fight human African trypanosomiasis, visceral leishmaniasis & Chagas disease](#)  
PharmaBiz: Nov 21 2009 6:11AM Matching: institut pasteur

- [Big pharma offer H1N1 vaccines at US\\$6.5-10 a dose](#)  
*VietNamNet Bridge: Nov 21 2009 7:14AM Matching: institut pasteur*
- [Novel protein implicated in genetic control](#)  
*Cordis: Nov 20 2009 8:50PM Matching: institut pasteur*
- [Pfizer and DNDi Advancing International Research Efforts In The Fight Against Neglected Tropical Diseases](#)  
*PharmaceuticalProcessing: Nov 20 2009 8:23PM Matching: institut pasteur*
- [Medical News: Pfizer, DNDi Partner To Identify NTD Drugs; Sanofi-Aventis, Medicines For Malaria Launch Drug Study](#)  
*BioFind: Nov 20 2009 3:58PM Matching: institut pasteur*
- [Medical News: Pfizer, DNDi Partner To Identify NTD Drugs; Sanofi-Aventis, Medicines For Malaria Launch Drug Study](#)  
*BioFind: Nov 20 2009 3:56PM Matching: institut pasteur*
- [Comprehensive report on world cancer therapies market](#)  
*News-Medical.Net: Nov 20 2009 6:46AM Matching: institut pasteur*
- [Big pharma offer H1N1 vaccines at US\\$6.5-10 a dose](#)  
*Thanhkien: Nov 20 2009 1:17PM Matching: institut pasteur*
- [Pfizer and DNDi to battle against HAT, VL and Chagas disease](#)  
*News-Medical.Net: Nov 19 2009 7:11AM Matching: institut pasteur*
- [Pfizer and DNDi Advancing International Research Efforts In The Fight Against Neglected Tropical Diseases](#)  
*Pharma Live: Nov 19 2009 2:12AM Matching: institut pasteur*
- [Pasteur Institute Joins National Spin-Off Program](#)  
*Individual.com: Nov 18 2009 4:55AM Matching: institut pasteur*
- [Pfizer and DNDi Advancing International Research Efforts In The Fight Against Neglected Tropical Diseases](#)  
*Yahoo! Canada: Nov 18 2009 7:37PM Matching: institut pasteur*
- [Pfizer and DNDi Advancing International Research Efforts In The Fight Against Neglected Tropical Diseases](#)  
*Genetic Engineering News: Nov 18 2009 2:55PM Matching: institut pasteur*
- [Pfizer and DNDi Advancing International Research Efforts In The Fight Against Neglected Tropical Diseases](#)  
*Business Wire via Yahoo!: Nov 18 2009 2:45PM Matching: institut pasteur*

## Institut Pasteur Patents:



- 7341731- [HIV-2 antigen compositions](#)
- 7399611- [Descendants of bacteria devoid of N terminal formylation useful for the production of proteins and peptides](#)
- 7413863- [Identification of substances that inhibit NEMO oligomerization](#)
- 7416851- [Method of diagnosis/prognosis of human chronic lymphocytic leukemia comprising the profiling of LPL/ADAM genes](#)
- 7417133- [Methods for obtaining thermostable enzymes, DNA polymerase I variants from Thermus aquaticus having new catalytic activities, methods for obtaining the same, and applications of the same](#)

- 7419789- [Method of inhibiting binding of Dengue virus to a human cell with DC-SIGN blockers](#)
- 7423020- [Treatment of mood disorders by administration of SMR1](#)
- 7427469- [Method of treating cytomegalovirus with DC-SIGN blockers](#)
- 7429448- [Therapeutic use of the SMR1 protein and active derivatives thereof](#)
- 7431928- [Identification of new CD8 epitopes from HIV-1 proteins](#)
- 7431936- [Proteins involved in cytoadhesion of plasmodium falciparum ring-stage-infected erythrocytes, antibodies which bind to the proteins, and methods for detecting infection, stage of infection and vaccines for protecting against infection](#)
- 7396812- [Method for modulating Nod1 activity, use of a MTP related molecule for modulating Nod1 activity, and therapeutic applications thereof](#)
- 7390875- [Method for binding, in solution, a peptide and a lipophilic vector and uses thereof](#)
- 7390872- [NF-.kappa.B peptides designed to disrupt NEMO oligomerization](#)
- 7345026- [Hybrid or chimeric polynucleotides, proteins, and compositions comprising hepatitis B virus sequences](#)
- 7351412- [Cloned DNA sequences related to the genomic RNA of lymphadenopathy-associated-virus \(LAV\) and proteins encoded by said LAV genomic RNA](#)
- 7361348- [Immunogenic glycopeptides, screening, preparation and uses](#)
- 7364744- [Synthetic peptide vaccines for HIV: the CBD epitope as an effective immunogen to elicit broadly neutralizing antibodies against HIV](#)
- 7364856- [PknB kinase and pstP phosphatase and methods of identifying inhibitory substances](#)
- 7368234- [Physical mapping method using molecular combing technique allowing positioning of a great number of clones within a genome](#)
- 7381555- [Lactobacillus N-deoxyribosyl transferases, corresponding nucleotide sequences and their uses](#)
- 7384740- [Polynucleotide and protein involved in synaptogenesis variants thereof and their therapeutic and diagnostic uses](#)
- 7387778- [Therapeutic methods and compositions for the treatment of impaired interpersonal and behavioral disorders](#)
- 7390495- [Neurovirulent strain of the West Nile virus and uses thereof](#)
- 7432251- [Methods of treating neurological diseases by regulating migration of neuroblasts in the adult nervous system with tenascin-R](#)
- 7435792- [Hybrid proteins that migrate retrogradely and transynaptically into the CNS](#)
- 7524646- [Method for diversifying the chemical composition of proteins produced in vivo by genetically disabling the editing function of their aminoacyl tRNA synthetases](#)
- 7527788- [Desaturase antigen of Mycobacterium tuberculosis](#)
- 7534877- [Non-M, non-O HIV-1 strains, fragments and uses](#)
- 7538206- [Comparative mycobacterial genomics as a tool for identifying targets for the diagnosis, prophylaxis or treatment of mycobacterioses](#)
- 7547513- [Mutants of deoxycytidine kinase having extended enzymatic activity](#)
- 7556812- [Dengue and West Nile viruses proteins and genes coding the foregoing, and their use in vaccinal, therapeutic and diagnostic applications](#)
- 7556939- [Identification and characterization of racemases, definition of protein signatures, and a test for detecting D-amino acid and for screening molecules capable of inhibiting the activity of racemase, especially proline racemase](#)
- 7563440- [Plasmodium falciparum antigens inducing protective antibodies](#)
- 7585619- [Method for detecting human immunodeficiency virus type 1 \(HIV-1\) reverse transcriptase \(RT\) activity](#)
- 7597896- [Composition comprising a protein encoded by a modified ERP gene of Mycobacterium](#)
- 7517666- [Methods of inhibiting Helicobacter pylori](#)
- 7507417- [Immunogenic compositions comprising human immunodeficiency virus type 2 \(HIV-2\) glycosylated and unglycosylated envelope proteins and their methods of preparation](#)
- 7498306- [Peptides binding to the phosphatase 2A protein](#)
- 7438917- [Peptide sequences specific for the hepatic stages of P. falciparum bearing epitopes capable](#)

[of stimulating the T lymphocytes](#)

- 7439053- [Transformed Shigella](#)
- 7465443- [Acellular antibordetella vaccine](#)
- 7473564- [Kit and method for detecting the ESM-1 protein](#)
- 7473772- [Chimeric GB virus B \(GBV-B\)](#)
- 7476719- [Mutated immunogenic peptides derived from R9M, polynucleotides coding for same and therapeutic uses thereof](#)
- 7488489- [Identification of a conserved region of Plasmodium falciparum MSP3 targeted by biologically active antibodies](#)
- 7488816- [Methods for obtaining thermostable enzymes, DNA polymerase I variants from Thermus aquaticus having new catalytic activities, methods for obtaining the same, and applications of the same](#)
- 7491404- [Acellular immunogenic compositions and acellular vaccine compositions against Bacillus anthracis](#)
- 7498037- [Plasmodium falciparum antigens and their vaccine and diagnostic applications](#)
- 7601350- [Antibodies that bind M. tuberculosis polypeptides](#)

## BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road,  
Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

